Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan

Yuki Saito; Ryuichi Hayashi; Yoshiyuki Iida; Takatsugu Mizumachi; Takashi Fujii; Fumihiko Matsumoto; Takeshi Beppu; Masafumi Yoshida; Hirotaka Shinomiya; Ryosuke Kamiyama; Mutsukazu Kitano; Kazuhiko Yokoshima; Yasushi Fujimoto; Takanori Hama; Taku Yamashita; Kenji Okami; Kouki Miura; Takuo Fujisawa; Daisuke Sano; Hisayuki Kato; Shujiro Minami; Masashi Sugasawa; Muneyuki Masuda; Ichiro Ota; Shigemichi Iwae; Ryo Kawata; Nobuya Monden; Takayuki Imai; Takahiro Asakage; Masafumi Okada; Takanori Yoshikawa; Kensuke Tanioka; Megumi Kitayama; Mariko Doi; Satoshi Fujii; Masato Fujii; Nobuhiko Oridate; Munenaga Nakamizo; Seiichi Yoshimoto; Akihiro Homma; Ken ichi Nibu; Katsunari Yane

doi:10.1002/cncr.33062

Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan

Yuki Saito, Ryuichi Hayashi, Yoshiyuki Iida, Takatsugu Mizumachi, Takashi Fujii, Fumihiko Matsumoto, Takeshi Beppu, Masafumi Yoshida, Hirotaka Shinomiya, Ryosuke Kamiyama, Mutsukazu Kitano, Kazuhiko Yokoshima, Yasushi Fujimoto, Takanori Hama, Taku Yamashita, Kenji Okami, Kouki Miura, Takuo Fujisawa, Daisuke Sano, Hisayuki KatoShujiro Minami, Masashi Sugasawa, Muneyuki Masuda, Ichiro Ota, Shigemichi Iwae, Ryo Kawata, Nobuya Monden, Takayuki Imai, Takahiro Asakage, Masafumi Okada, Takanori Yoshikawa, Kensuke Tanioka, Megumi Kitayama, Mariko Doi, Satoshi Fujii, Masato Fujii, Nobuhiko Oridate, Munenaga Nakamizo, Seiichi Yoshimoto, Akihiro Homma, Ken ichi Nibu, Katsunari Yane

Department of Otolaryngology ・ Head and Neck Surgery

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Background: Although the American Joint Committee on Cancer TNM classification has been amended to include human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma (OPSCC) as an independent entity, to the authors' knowledge the optimized de-escalating treatment modality has not been established to date. Methods: The authors conducted a retrospective, nationwide, observational study in patients with HPV-related OPSCC who were treated from 2011 to 2014 in Japan to determine the best treatment modality. Results: A total of 688 patients who were newly diagnosed with HPV-related OPSCC who were treated with curative intent at 35 institutions and had coherent clinical information and follow-up data available were included in the current study. In patients with T1-T2N0 disease (79 patients), both the 3-year recurrence-free survival and overall survival (OS) rates were 100% in the group treated with radiotherapy (RT) as well as the group receiving concurrent chemoradiotherapy (CCRT). The 3-year OS rates were 94.4% (for patients with T1N0 disease) and 92.9% (for patients with T2N0 disease) among the patients treated with upfront surgery. In patients with stage I to stage II HPV-related OPSCC, the 5-year recurrence-free survival and OS rates were 91.4% and 92%, respectively, in the patients treated with CCRT with relatively high-dose cisplatin (≥160 mg/m²; 114 patients) and 74.3% and 69.5%, respectively, in the patients treated with low-dose cisplatin (<160 mg/m²; 17 patients). Conclusions: Despite it being a retrospective observational trial with a lack of information regarding toxicity and morbidity, the results of the current study demonstrated that patients with T1-T2N0 HPV-related OPSCC could be treated with RT alone because of the equivalent outcomes of RT and CCRT, and patients with stage I to stage II HPV-related OPSCC other than those with T1-T2N0 disease could be treated with CCRT with cisplatin at a dose of ≥160 mg/m².

Original language	English
Pages (from-to)	4177-4187
Number of pages	11
Journal	Cancer
Volume	126
Issue number	18
DOIs	https://doi.org/10.1002/cncr.33062
Publication status	Published - 15-09-2020

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cncr.33062

Cite this

Saito, Y., Hayashi, R., Iida, Y., Mizumachi, T., Fujii, T., Matsumoto, F., Beppu, T., Yoshida, M., Shinomiya, H., Kamiyama, R., Kitano, M., Yokoshima, K., Fujimoto, Y., Hama, T., Yamashita, T., Okami, K., Miura, K., Fujisawa, T., Sano, D., ... Yane, K. (2020). Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan. Cancer, 126(18), 4177-4187. https://doi.org/10.1002/cncr.33062

@article{aa5062b473f145578e23c60209a6e9d2,

title = "Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan",

abstract = "Background: Although the American Joint Committee on Cancer TNM classification has been amended to include human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma (OPSCC) as an independent entity, to the authors' knowledge the optimized de-escalating treatment modality has not been established to date. Methods: The authors conducted a retrospective, nationwide, observational study in patients with HPV-related OPSCC who were treated from 2011 to 2014 in Japan to determine the best treatment modality. Results: A total of 688 patients who were newly diagnosed with HPV-related OPSCC who were treated with curative intent at 35 institutions and had coherent clinical information and follow-up data available were included in the current study. In patients with T1-T2N0 disease (79 patients), both the 3-year recurrence-free survival and overall survival (OS) rates were 100% in the group treated with radiotherapy (RT) as well as the group receiving concurrent chemoradiotherapy (CCRT). The 3-year OS rates were 94.4% (for patients with T1N0 disease) and 92.9% (for patients with T2N0 disease) among the patients treated with upfront surgery. In patients with stage I to stage II HPV-related OPSCC, the 5-year recurrence-free survival and OS rates were 91.4% and 92%, respectively, in the patients treated with CCRT with relatively high-dose cisplatin (≥160 mg/m2; 114 patients) and 74.3% and 69.5%, respectively, in the patients treated with low-dose cisplatin (<160 mg/m2; 17 patients). Conclusions: Despite it being a retrospective observational trial with a lack of information regarding toxicity and morbidity, the results of the current study demonstrated that patients with T1-T2N0 HPV-related OPSCC could be treated with RT alone because of the equivalent outcomes of RT and CCRT, and patients with stage I to stage II HPV-related OPSCC other than those with T1-T2N0 disease could be treated with CCRT with cisplatin at a dose of ≥160 mg/m2.",

keywords = "Japan, head and neck squamous cell carcinoma (HNSCC), human papillomavirus (HPV), oropharyngeal carcinoma, p16",

author = "Yuki Saito and Ryuichi Hayashi and Yoshiyuki Iida and Takatsugu Mizumachi and Takashi Fujii and Fumihiko Matsumoto and Takeshi Beppu and Masafumi Yoshida and Hirotaka Shinomiya and Ryosuke Kamiyama and Mutsukazu Kitano and Kazuhiko Yokoshima and Yasushi Fujimoto and Takanori Hama and Taku Yamashita and Kenji Okami and Kouki Miura and Takuo Fujisawa and Daisuke Sano and Hisayuki Kato and Shujiro Minami and Masashi Sugasawa and Muneyuki Masuda and Ichiro Ota and Shigemichi Iwae and Ryo Kawata and Nobuya Monden and Takayuki Imai and Takahiro Asakage and Masafumi Okada and Takanori Yoshikawa and Kensuke Tanioka and Megumi Kitayama and Mariko Doi and Satoshi Fujii and Masato Fujii and Nobuhiko Oridate and Munenaga Nakamizo and Seiichi Yoshimoto and Akihiro Homma and Nibu, {Ken ichi} and Katsunari Yane",

note = "Publisher Copyright: {\textcopyright} 2020 American Cancer Society",

year = "2020",

month = sep,

day = "15",

doi = "10.1002/cncr.33062",

language = "English",

volume = "126",

pages = "4177--4187",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "18",

}

Saito, Y, Hayashi, R, Iida, Y, Mizumachi, T, Fujii, T, Matsumoto, F, Beppu, T, Yoshida, M, Shinomiya, H, Kamiyama, R, Kitano, M, Yokoshima, K, Fujimoto, Y, Hama, T, Yamashita, T, Okami, K, Miura, K, Fujisawa, T, Sano, D, Kato, H, Minami, S, Sugasawa, M, Masuda, M, Ota, I, Iwae, S, Kawata, R, Monden, N, Imai, T, Asakage, T, Okada, M, Yoshikawa, T, Tanioka, K, Kitayama, M, Doi, M, Fujii, S, Fujii, M, Oridate, N, Nakamizo, M, Yoshimoto, S, Homma, A, Nibu, KI & Yane, K 2020, 'Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan', Cancer, vol. 126, no. 18, pp. 4177-4187. https://doi.org/10.1002/cncr.33062

Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan. / Saito, Yuki; Hayashi, Ryuichi; Iida, Yoshiyuki et al.
In: Cancer, Vol. 126, No. 18, 15.09.2020, p. 4177-4187.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma

T2 - Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan

AU - Saito, Yuki

AU - Hayashi, Ryuichi

AU - Iida, Yoshiyuki

AU - Mizumachi, Takatsugu

AU - Fujii, Takashi

AU - Matsumoto, Fumihiko

AU - Beppu, Takeshi

AU - Yoshida, Masafumi

AU - Shinomiya, Hirotaka

AU - Kamiyama, Ryosuke

AU - Kitano, Mutsukazu

AU - Yokoshima, Kazuhiko

AU - Fujimoto, Yasushi

AU - Hama, Takanori

AU - Yamashita, Taku

AU - Okami, Kenji

AU - Miura, Kouki

AU - Fujisawa, Takuo

AU - Sano, Daisuke

AU - Kato, Hisayuki

AU - Minami, Shujiro

AU - Sugasawa, Masashi

AU - Masuda, Muneyuki

AU - Ota, Ichiro

AU - Iwae, Shigemichi

AU - Kawata, Ryo

AU - Monden, Nobuya

AU - Imai, Takayuki

AU - Asakage, Takahiro

AU - Okada, Masafumi

AU - Yoshikawa, Takanori

AU - Tanioka, Kensuke

AU - Kitayama, Megumi

AU - Doi, Mariko

AU - Fujii, Satoshi

AU - Fujii, Masato

AU - Oridate, Nobuhiko

AU - Nakamizo, Munenaga

AU - Yoshimoto, Seiichi

AU - Homma, Akihiro

AU - Nibu, Ken ichi

AU - Yane, Katsunari

PY - 2020/9/15

Y1 - 2020/9/15

N2 - Background: Although the American Joint Committee on Cancer TNM classification has been amended to include human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma (OPSCC) as an independent entity, to the authors' knowledge the optimized de-escalating treatment modality has not been established to date. Methods: The authors conducted a retrospective, nationwide, observational study in patients with HPV-related OPSCC who were treated from 2011 to 2014 in Japan to determine the best treatment modality. Results: A total of 688 patients who were newly diagnosed with HPV-related OPSCC who were treated with curative intent at 35 institutions and had coherent clinical information and follow-up data available were included in the current study. In patients with T1-T2N0 disease (79 patients), both the 3-year recurrence-free survival and overall survival (OS) rates were 100% in the group treated with radiotherapy (RT) as well as the group receiving concurrent chemoradiotherapy (CCRT). The 3-year OS rates were 94.4% (for patients with T1N0 disease) and 92.9% (for patients with T2N0 disease) among the patients treated with upfront surgery. In patients with stage I to stage II HPV-related OPSCC, the 5-year recurrence-free survival and OS rates were 91.4% and 92%, respectively, in the patients treated with CCRT with relatively high-dose cisplatin (≥160 mg/m2; 114 patients) and 74.3% and 69.5%, respectively, in the patients treated with low-dose cisplatin (<160 mg/m2; 17 patients). Conclusions: Despite it being a retrospective observational trial with a lack of information regarding toxicity and morbidity, the results of the current study demonstrated that patients with T1-T2N0 HPV-related OPSCC could be treated with RT alone because of the equivalent outcomes of RT and CCRT, and patients with stage I to stage II HPV-related OPSCC other than those with T1-T2N0 disease could be treated with CCRT with cisplatin at a dose of ≥160 mg/m2.

AB - Background: Although the American Joint Committee on Cancer TNM classification has been amended to include human papillomavirus (HPV)–related oropharyngeal squamous cell carcinoma (OPSCC) as an independent entity, to the authors' knowledge the optimized de-escalating treatment modality has not been established to date. Methods: The authors conducted a retrospective, nationwide, observational study in patients with HPV-related OPSCC who were treated from 2011 to 2014 in Japan to determine the best treatment modality. Results: A total of 688 patients who were newly diagnosed with HPV-related OPSCC who were treated with curative intent at 35 institutions and had coherent clinical information and follow-up data available were included in the current study. In patients with T1-T2N0 disease (79 patients), both the 3-year recurrence-free survival and overall survival (OS) rates were 100% in the group treated with radiotherapy (RT) as well as the group receiving concurrent chemoradiotherapy (CCRT). The 3-year OS rates were 94.4% (for patients with T1N0 disease) and 92.9% (for patients with T2N0 disease) among the patients treated with upfront surgery. In patients with stage I to stage II HPV-related OPSCC, the 5-year recurrence-free survival and OS rates were 91.4% and 92%, respectively, in the patients treated with CCRT with relatively high-dose cisplatin (≥160 mg/m2; 114 patients) and 74.3% and 69.5%, respectively, in the patients treated with low-dose cisplatin (<160 mg/m2; 17 patients). Conclusions: Despite it being a retrospective observational trial with a lack of information regarding toxicity and morbidity, the results of the current study demonstrated that patients with T1-T2N0 HPV-related OPSCC could be treated with RT alone because of the equivalent outcomes of RT and CCRT, and patients with stage I to stage II HPV-related OPSCC other than those with T1-T2N0 disease could be treated with CCRT with cisplatin at a dose of ≥160 mg/m2.

KW - Japan

KW - head and neck squamous cell carcinoma (HNSCC)

KW - human papillomavirus (HPV)

KW - oropharyngeal carcinoma

KW - p16

UR - http://www.scopus.com/inward/record.url?scp=85087674005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087674005&partnerID=8YFLogxK

U2 - 10.1002/cncr.33062

DO - 10.1002/cncr.33062

M3 - Article

C2 - 32648953

AN - SCOPUS:85087674005

SN - 0008-543X

VL - 126

SP - 4177

EP - 4187

JO - Cancer

JF - Cancer

IS - 18

ER -

Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national Head and Neck Cancer Registry of Japan

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this